Regular articleRandomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma☆
References (20)
- Unpublished...
- et al.
Prolonged combination chemotherapy for ovarian carcinoma does not increase the rate of surgical complete remission
- et al.
Advanced ovarian cancer: Brief intensive combination chemotherapy and second-look operation
Obstet. Gynecol.
(1981) - et al.
Randomized trial comparing two combination chemotherapy regimens (CAP-5 v CP) in advanced ovarian carcinoma
J. Clin. Oncol.
(1987) - et al.
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study
J. Clin. Oncol.
(1989) Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer
Lancet
(1987)- et al.
Nonparametric estimation from incomplete observations
J. Am. Stat. Assoc.
(1958) - et al.
A randomized trial of six versus twelve cycles of cyclophosphamide, adriamycin in advanced ovarian cancer
- et al.
Long-term versus short-term chemotherapy in advanced ovarian cancer
Cited by (153)
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study
2018, Gynecologic OncologyCitation Excerpt :Increasing the number of cycles or the dose of chemotherapy per cycle has not resulted in any significant therapeutic advantage in terms of progression-free survival (PFS) or OS [5]. It has been previously shown that similar outcomes were seen in patients treated with 5 versus 12 cycles of chemotherapy [6–9]. Nonetheless, there are reasons to believe that completing the number of prescribed chemotherapy cycles on schedule without dose reduction may be associated with improved clinical outcomes.
Epithelial ovarian cancer
2018, Clinical Gynecologic OncologyNeoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study
2017, Gynecologic OncologyCitation Excerpt :Hakes et al. (1992) first performed a prospective randomized control trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin (CAP) every 4 weeks. The authors found no difference in OS or CCR rate [24]. Bertelsen et al. (1993) examined 202 patients with 6 versus 12 cycles of CAP, and also found no difference in OS [25].
Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review
2015, Materials Science and Engineering CLong-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer
2014, European Journal of CancerCitation Excerpt :Previous studies have shown conflicting results of prolonging chemotherapy in first-line EOC beyond six cycles. Two prior studies showed no benefit, confirming our results, and in one study median PFS was improved without improvement in OS and at the cost of increased toxicity [23–25]. Ethnicity may partly explain the different outcomes of the above-mentioned clinical trials.
- ☆
Supported in part by the Avon Program for Ovarian Cancer and NCI CA5826-23.